Guselkumab

REQUEST MORE INFO
Catalogue No: abx831285
Price: US$464.00
(Size: 100 µg)

Click on the image to see the image legend

Available Options

* Size:


Add to Shopping Cart Buy It Now GET A QUOTE

Documents

Datasheet SDS
Guselkumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL23A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation 2. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.

Target IL23A
Clonality Monoclonal
Reactivity Human
Expression Recombinant
Tested Applications ELISA, WB
Host Human
Recommended dilutions Optimal dilutions/concentrations should be determined by the end user.
Conjugation Unconjugated
Isotype IgG1 Lambda
Form Liquid
Purity > 95%
Purification Purified from cell culture supernatants by Protein A/G chromatography.
Storage Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer 0.01 M PBS. pH 7.4.
CAS Number 1350289-85-8
Concentration Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability Shipped within 7-12 working days.
Note This product is for research use only.

Not for human consumption, cosmetic, therapeutic or diagnostic use.
Research Articles on IL23A


Write a review

Tags:
(Click to show)